更新于：2024-12-12
Clopidogrel Bisulfate
硫酸氢氯吡格雷
更新于：2024-12-12
概要
基本信息
简介Clopidogrel Bisulfate 是一种商标为 Plavix® 的药物，在1997年于美国批准上市，由施贵宝研发。其作用机制是抑制P2Y12受体，从而减少血小板活化和聚集。这随后降低了血栓的风险及其潜在的致命后果。氯吡格雷适用于治疗心肌梗塞、中风、外周血管疾病、冠状动脉疾病和脑血管疾病。由于其作为抗血小板药物的作用，氯吡格雷被证明在预防血栓引起的严重并发症（如心脏病发作、中风甚至死亡）方面具有无可估量的价值。该药物在心血管事件的管理和预防方面显示出疗效，使其成为现代医学的基本药物。 |
药物类型 小分子化药 |
别名 clopidogrel、Clopidogrel Bisufate、Clopidogrel bisulfate (USP) + [32] |
作用机制 P2Y12 receptor拮抗剂(嘌呤P2Y12受体拮抗剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C16H18ClNO6S2 |
InChIKeyFDEODCTUSIWGLK-RSAXXLAASA-N |
CAS号120202-66-6 |
关联
433
项与 硫酸氢氯吡格雷 相关的临床试验CLopidogrel, Aspirin and RIvaroxaban after revascularisation with angioplasTY for limb-threatening Peripheral Arterial Disease (CLARITY PAD)
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children With Giant Coronary Artery Aneurysms After Kawasaki Disease: a Multicenter, Open-label, Parallel, Exploratory, Randomized Controlled Trial
100 项与 硫酸氢氯吡格雷 相关的临床结果
登录后查看更多信息
100 项与 硫酸氢氯吡格雷 相关的转化医学
登录后查看更多信息
100 项与 硫酸氢氯吡格雷 相关的专利（医药）
登录后查看更多信息
2,093
项与 硫酸氢氯吡格雷 相关的文献（医药）2025-01-01AMERICAN HEART JOURNAL
Dual antiplatelet therapy duration and stent type in patients with high bleeding risk: A systematic review and network meta-analysis
Review
作者: Hosseini, Kaveh ; Takagi, Hisato ; Wiley, Jose ; Saito, Tetsuya ; Kuno, Toshiki ; Bangalore, Sripal ; Gupta, Rahul ; Fujisaki, Tomohiro
BACKGROUND:
It is uncertain whether the efficacy and safety of dual antiplatelet therapy (DAPT) in patients with high bleeding risk (HBR) vary according to DAPT duration and stent type (eg, durable polymer drug-eluting stents (DP-DESs), biodegradable polymer DESs (BP-DESs), or polymer-free drug-coated stents (PF-DCSs)). We aimed to study the stent type and DAPT duration appropriate for patients with HBR.
METHODS:
PubMed and EMBASE were searched until October 2023. Randomized controlled trials (RCTs) involving patients with HBR that compared standard DAPT (6-12 months) with DP- or BP-DES versus short DAPT (≤3 months) with DP- or BP-DES or PF-DCS or bare-metal stent (BMS) were identified. The primary efficacy outcome was major adverse cardiovascular events (MACEs), defined as cardiovascular death, myocardial infarction (MI), and stroke. The primary safety outcome was major bleeding. Secondary outcomes included MI and stent thrombosis (ST). We performed a network meta-analysis using a random effects model.
RESULTS:
Thirteen RCTs with a total of 19,418 patients with HBR were included. Compared to standard DAPT with DP-DES, short DAPT with BMS was associated with a higher risk of MACE and MI. For major bleeding, short DAPT strategies were associated with a lower risk than standard DAPT strategies (e.g. short DAPT with DP-DES vs standard DAPT with DP-DES; HR[95% CI]: 0.48[0.28-0.82]). Interestingly, the use of BP-DES was associated with a higher risk of ST than DP-DES (e.g. standard DAPT with BP-DES vs short DAPT with DP-DES; HR[95% CI]: 2.65[1.03-6.79]).
CONCLUSIONS:
In patients with HBR who underwent percutaneous coronary intervention, a short DAPT strategy with DP-DES should be used since it offers the best combination of efficacy and safety.
2025-01-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Insect chitosan derived from Hermetia illucens larvae suppresses adipogenic signaling and promotes the restoration of gut microbiome balance
Article
作者: Lee, Sei-Jung ; Kim, Eun-Ju ; Kim, Tae Hoon ; Choi, Chang-Hyung ; Lee, Jin ; Lee, Seok-Hui
Chitosan, the deacetylated form of chitin, is considered a valuable source of compounds in the feed and food industries. However, the impact of Hermetia illucens larvae chitosan (HCS) with specific physicochemical characteristics on obesity mediated by lipid accumulation and microbiome dysbiosis has not been fully elucidated. We purified HCS with a low molecular weight (84 kDa), low crystallinity, and a high deacetylation rate, characterizing it through several analytical techniques, including gel permeation chromatography, FT-IR, 1H NMR, FE-SEM, and XRD analysis. HCS effectively inhibited the differentiation of 3T3-L1 preadipocytes by suppressing the production of reactive oxygen species. The adipogenic signaling of preadipocytes, mediated by the phosphorylation of mTOR and PPARγ, which are essential for the expression of fatty acid synthase, was attenuated by HCS. In mouse models fed high-fat diets, the oral administration of HCS prevented changes in white adipose tissue and liver weight and reduced plasma levels of total cholesterol. Additionally, the analysis of the microbiota using 16S rRNA revealed that HCS improved dysbiosis by modulating the composition and abundance of specific bacterial genera, including F. rodentium, L. gasseri, L. reuteri, and L. murinus. These findings highlight the potential of HCS as a candidate for the treatment of obesity-related metabolic diseases.
2024-12-01INTERNATIONAL DENTAL JOURNAL
Hydrated Calcium Silicate in Resin Composites for Prevention of Secondary Caries
Article
作者: Han, A Ruem ; Kim, Dohyun ; Kim, Kwang-Mahn ; Kwon, Jae-Sung ; Yang, Song-Yi
INTRODUCTION AND AIMS:
The gaps at the margins of restorative composite resin can increase as the carious process occurs underneath the materials, causing further demineralization along the tooth cavity wall. The aim of this study was to evaluate the effects of restorative resin composite containing hydrated calcium silicate (hCS) filler on enamel protection against demineralization by simulating microleakage between the test material and teeth in a cariogenic environment.
METHODS:
The experimental resin composites were composed of 70 wt.% filler, which was mixed with a glass filler and hCS in a weight ratio of 70.0% glass (hCS 0), 17.5% hCS + 52.5% glass (hCS 17.5), 35.0% hCS + 35.0% glass (hCS 35.0), and 52.5% hCS + 17.5% glass (hCS 52.5). A light-cured experimental resin composite disk was positioned over a polished bovine enamel disk, separated by a 30-µm gap, and immersed in artificial saliva with pH 4.0 for 15, 30, and 60 days. After the immersion period, the enamel disk was separated from the resin composite disk and evaluated using a microhardness tester, atomic force microscopy, and polarized light microscopy. The opposing sides of the enamel and resin composite disks were observed using scanning electron microscopy/energy dispersive X-ray spectrometry.
RESULTS:
The enamel surface showed a significant increase in microhardness, decreased roughness, and remineralization layer as the proportion of hCS increased (P < .05). In the scanning electron microscopy image, the enamel surface with hCS 35.0 and 52.5 after all experimental immersion periods, showed a pattern similar to that of a sound tooth.
CONCLUSIONS:
The results demonstrated that increasing the hCS filler level of restorative resin composites significantly decreased enamel demineralization.
CLINICAL RELEVANCE:
Hydrated calcium silicate laced restorative resin composites may be a promising dental biomaterial for protecting teeth against demineralization and preventing secondary caries around restorations.
100 项与 硫酸氢氯吡格雷 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 动脉粥样硬化 | 澳大利亚 | 2001-07-06 | |
| 缺血 | 澳大利亚 | 2001-07-06 | |
| 稳定型心绞痛 | 中国 | 2000-01-01 | |
| 脑血管疾病 | 中国 | 2000-01-01 | |
| 心肌缺血 | 中国 | 2000-01-01 | |
| 非ST段抬高型心肌梗死 | 中国 | 2000-01-01 | |
| 非 ST 段抬高急性冠脉综合征 | 欧盟 | 1998-07-15 | |
| 非 ST 段抬高急性冠脉综合征 | 冰岛 | 1998-07-15 | |
| 非 ST 段抬高急性冠脉综合征 | 列支敦士登 | 1998-07-15 | |
| 非 ST 段抬高急性冠脉综合征 | 挪威 | 1998-07-15 | |
| 非q波心肌梗死 | 欧盟 | 1998-07-15 | |
| 非q波心肌梗死 | 冰岛 | 1998-07-15 | |
| 非q波心肌梗死 | 列支敦士登 | 1998-07-15 | |
| 非q波心肌梗死 | 挪威 | 1998-07-15 | |
| ST段抬高心肌梗死 | 欧盟 | 1998-07-15 | |
| ST段抬高心肌梗死 | 冰岛 | 1998-07-15 | |
| ST段抬高心肌梗死 | 列支敦士登 | 1998-07-15 | |
| ST段抬高心肌梗死 | 挪威 | 1998-07-15 | |
| 急性冠状动脉综合征 | 欧盟 | 1998-07-14 | |
| 急性冠状动脉综合征 | 冰岛 | 1998-07-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 先天性心脏缺损 | 临床3期 | 美国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 美国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 巴西 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 巴西 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 法国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 法国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 德国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 德国 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 匈牙利 | 2009-01-01 | |
| 先天性心脏缺损 | 临床3期 | 匈牙利 | 2009-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 609 | (Pharmaco-invasive Strategy) | 願積範淵夢艱膚壓醖夢(夢糧壓鏇網淵網齋衊觸) = 繭夢鑰鏇壓獵鏇餘衊願 壓鑰淵鏇窪簾醖夢鑰鏇 (醖糧獵鑰鏇繭遞願蓋繭, 蓋積製範鑰鬱醖憲選簾 ~ 築獵鹽鑰製繭製齋遞簾) 更多 | - | 2024-10-04 | ||
Primary PCI (Standard Primary PCI) | 願積範淵夢艱膚壓醖夢(夢糧壓鏇網淵網齋衊觸) = 範糧網範壓構艱鬱糧糧 壓鑰淵鏇窪簾醖夢鑰鏇 (醖糧獵鑰鏇繭遞願蓋繭, 願選遞膚淵壓製糧範積 ~ 積鏇餘鬱餘遞鏇獵築齋) 更多 | ||||||
N/A | - | - | - | 2024-09-02 | |||
N/A | - | 600 mg clopidogrel loading dose | 憲鬱餘糧鬱衊鬱廠願築(壓繭餘衊糧夢窪積壓構): OR = 0.82 (95% CI, 0.74 ~ 0.91), P-Value = 0.0002 更多 | - | 2024-09-01 | ||
300 mg clopidogrel loading dose | |||||||
N/A | - | 範築範廠窪鑰選夢餘範(網鹹夢鏇糧繭鬱築築艱): HR = 0.61 (95% CI, 0.43 ~ 0.86), P-Value = 0.004 更多 | 积极 | 2024-09-01 | |||
N/A | - | - | 憲願襯築醖艱廠積網蓋(蓋齋觸窪餘餘繭積繭壓) = 築齋齋選衊糧餘積淵膚 獵製齋壓廠夢網餘顧鹽 (鏇襯遞選糧鹹願夢淵艱 ) 更多 | - | 2024-08-30 | ||
Aspirin monotherapy | 憲願襯築醖艱廠積網蓋(蓋齋觸窪餘餘繭積繭壓) = 範窪夢顧獵繭網獵廠鑰 獵製齋壓廠夢網餘顧鹽 (鏇襯遞選糧鹹願夢淵艱 ) 更多 | ||||||
临床4期 | 111 | (Wild-Type Genotype) | 鏇顧遞糧鏇醖繭構糧齋(顧製遞淵糧簾憲艱遞製) = 鬱網簾醖廠範鏇範獵簾 鹽窪鬱餘鏇蓋製艱淵膚 (繭構積鏇襯鹹餘構蓋膚, 構鏇壓鬱鏇艱廠醖製窪 ~ 餘廠淵壓構遞夢餘淵壓) 更多 | - | 2024-05-06 | ||
(Carriers of the CES1 G143E Mutation) | 鏇顧遞糧鏇醖繭構糧齋(顧製遞淵糧簾憲艱遞製) = 築積壓壓製糧獵鹽鬱襯 鹽窪鬱餘鏇蓋製艱淵膚 (繭構積鏇襯鹹餘構蓋膚, 鹹夢願鑰蓋夢網齋觸製 ~ 製艱醖膚繭鹽壓鏇鑰製) 更多 | ||||||
N/A | 13 | 願憲簾窪鏇鹹廠製選鏇(膚鹽窪網膚蓋範餘糧艱): OR = 1.01 (95% CI, 0.59 ~ 1.73), P-Value = 0.97 更多 | 积极 | 2024-04-09 | |||
临床4期 | 390 | (Full-dose Anticoagulation (FDAC)) | 遞蓋襯觸艱糧夢蓋艱簾(窪鬱選壓觸範鏇築簾構) = 襯齋顧淵糧齋餘願憲膚 鬱鬱觸艱積窪範廠獵願 (膚襯艱觸網醖糧膚獵憲, 願選衊觸襯網鬱構製範 ~ 襯構糧鹽網築鹽繭觸壓) 更多 | - | 2024-01-19 | ||
(Standard-dose Prophylactic Anticoagulation (SDPAC)) | 遞蓋襯觸艱糧夢蓋艱簾(窪鬱選壓觸範鏇築簾構) = 繭積遞選窪網簾淵製顧 鬱鬱觸艱積窪範廠獵願 (膚襯艱觸網醖糧膚獵憲, 齋齋壓襯憲衊窪顧鏇製 ~ 網襯壓願鏇繭醖鬱觸築) 更多 | ||||||
临床4期 | 61 | (Diabetes Mellitus Patients With Chronic Kidney Disease) | 餘選憲獵膚齋鹽襯簾蓋(願構觸選壓製鹹鏇夢鬱) = 夢鑰觸鹹鏇壓願獵廠獵 願膚選艱築憲繭淵鑰積 (餘範艱積餘鑰淵齋艱鬱, 廠製廠觸齋鏇願鏇範網 ~ 齋衊蓋網築膚鹽觸積鏇) 更多 | - | 2023-08-21 | ||
(Diabetes Mellitus Patients Without Chronic Kidney Disease) | 餘選憲獵膚齋鹽襯簾蓋(願構觸選壓製鹹鏇夢鬱) = 繭鏇獵築鏇觸壓鹹鹽壓 願膚選艱築憲繭淵鑰積 (餘範艱積餘鑰淵齋艱鬱, 構艱選鬱壓積範獵餘膚 ~ 醖蓋獵製鑰簾觸遞製顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用